Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

JAK1/2 inhibitors tied to increased B-cell lymphoma risk

Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.

Key clinical point: JAK1/2 inhibition in patients with myeloproliferative neoplasms is linked to a higher risk of aggressive lymphoma.

Major finding: Patients with myeloproliferative neoplasms treated with JAK1/2 inhibitors have a 16-fold higher incidence of lymphoma.

Study details: A retrospective cohort study of 626 patients with myeloproliferative neoplasms.

Disclosures: The study was supported by the Austrian Science Fund, the Anniversary Fund of the Austrian National Bank, and the WWTF Precision Medicine Program. Several authors reported support, funding, or advisory board positions with the pharmaceutical industry.

Read the article.

Citation:

Porpaczy E et al. Blood. 2018 Jun 14. doi: 10.1182/blood-2017-10-810739.